Superior pain relief in Chronic Venous Disease patients undergoing after endovenous thermal ablation together with the Micronized Purified Flavonoid Fraction (MPFF).
The aim of the study was to evaluate the role of the Micronized Purified Flavonoid Fraction (MPFF) in the improvement of postoperative symptoms after endovenous thermal ablation (EVTA).
A prospective comparative study of 120 consecutive patients undergoing EVTA of the greater saphenous vein associated with phlebectomies was undertaken. Patients were grouped in those receiving the Micronized Purified Flavonoid Fraction (MPFF- 60 patients) agent 500 mg Bid 7 days pre-and 30 days post-operatively (MPFF group) and those in the control group (60 patients) who did not.
Demographics, intra-operative details, Clinical -Etiology- Anatomy- Pathophysiology (CEAP) clinical class, 10-cm Visual Analog Scale (VAS) for pain, Venous Clinical Severity Score (VCSS), and Chronic Venous Disease Quality-of-Life Questionnaire (CΙVIQ-20) were recorded. The primary outcome was the postoperative pain assessment using the VAS scale and CIVIQ pain score. Secondary outcomes included assessment of VCSS and CΙVIQ-20 scores.
There were no significant differences between the groups regarding demographics, clinical and procedural characteristics. Patients in MPFF group reported significantly lower VAS pain levels than control group at 7- (-3.6 ± 1.2 vs -2.7 ± 1.9, p < .0001) and 30- post-operative day (-4.9 ± 0.1 vs -4.2 ± 1, p < .0001). MPFF group also showed better outcome in terms of CIVIQ pain score at 7- (-3.7 ± 1.3 vs -3.5 ± 1.8,p = .008) and 30- post-operative day (-5.3. ± 1.1 vs -4.4 ± 1, p = .017). Both groups showed a significant improvement in VAS pain score (p = .047), global CIVIQ-20 (p = .009) and VCSS (p = .008) at 7- and 30-days post-operatively.
Administration of the Micronized Purified Flavonoid Fraction (MPFF) in patients undergoing EVTA associated with phlebectomies reduces pain by a small amount during the early postoperative period.
To know more : Click here
Keep up to date with our content
Subscribe to our newsletter so that you are always up to date with the news.